NCE-1 Intelligence & Market Opportunity

Imjudo

Tremelimumab

Anticancer

Intravenous Injectable

Approval Date

21-Oct-22

NCE-1 Date

21-Oct-26

NCE Date

21-Oct-27

Commercial snapshot

Market performance & projections

Revenue ($M)

346

CAGR (%)

0.1083

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

404

2027

458

2028

495

2029

522

2030

548

2031

574

2032

581

Molecule profile

Details & specifications

Molecule

Tremelimumab

Innovator

ASTRAZENECA PHARMACEUTICALS LP

Dosage Form

Intravenous Injectable

Strength

25 mg/1.25 mL (20 mg/mL), 300 mg/15 mL (20 mg/mL)

Therapeutic Category

Anticancer

Usage

To treat unresectable hepatocellular carcinoma

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.